Phytochemical Investigation and Evaluation of Antibacterial Activity of Zizyphus Xylopyrus (Retz) Willd Leaf Extract

An experiment was carried out to evaluate the antibacterial activity of the Zizyphus xylopyrus ethanolic fractions, which was related to the phytoconstituents present. The plant's root powder was extracted using an ethanol extraction procedure that involved several consecutive steps. Following this, the extracted product displayed a distinct scent feature. Tannic acid, phenol, and flavonoids were found, indicating the existence of the required phytochemicals. The flavonoids were isolated using spectroscopic characterisation using the ethanolic extract. After then, this extract was used for additional pharmacological testing because in the study, only ethanolic extracts and saponins were used. Based on each sample's results from a variety of qualitative tests, this analysis was carried out. The discovery of new illnesses, especially those brought on by Enterococcus and Staphylococcus species, has sparked increased interest in the study of therapeutic plants in recent decades. These microorganisms have become resistant to widely used antibiotics and are the cause of a considerable proportion of hospital-acquired illnesses. For example, S. aureus, which was once sensitive to a number of antibiotics, is now showing signs of resistance to several medication

Aggregate dust model to study the polarization properties of comet C/1996 B2 Hyakutake

In our present study, the observed linear polarization data of comet Hyakutake are studied at wavelengths $\lambda=0.365\mu m$, $\lambda=0.485\mu m$ and 0.684$\mu m$ through simulations using Ballistic Particle-Cluster Aggregate and Ballistic Cluster-Cluster Aggregate aggregates of 128 spherical monomers. We first investigated that the size parameter of the monomer, $x$ $\sim$ 1.56 -- 1.70, turned out to be most suitable which provides the best fits to the observed dust scattering properties at three wavelengths $\lambda = 0.365$$\mu m$, 0.485$\mu m$ and 0.684$\mu m$. Thus the effective radius of the aggregate (r) lies in the range $0.45 \mu m \le r \le 0.49 \mu m$ at $\lambda = 0.365$$\mu m$; $0.60 \mu m \le r \le 0.66 \mu m$ at $\lambda = 0.485$$\mu m$ and $0.88 \mu m \le r \le 0.94 \mu m$ at $\lambda = 0.684$$\mu m$. Now using superposition \textsc{t-matrix} code and the power-law size distribution, $n(r) \sim r^{-3}$, the best-fitting values of complex refractive indices are calculated which can best fit the observed polarization data at the above three wavelengths. The best-fitting complex refractive indices $(n,k)$ are found to be (1.745, 0.095) at $\lambda = 0.365$ $\mu m$, (1.743, 0.100) at $\lambda = 0.485$ $\mu m$ and (1.695, 0.100) at $\lambda = 0.684$ $\mu m$. The refractive indices coming out from the present analysis correspond to mixture of both silicates and organics, which are in good agreement with the \textit{in situ} measurement of comets by different spacecraft.Comment: 9 pages, 3 figure

Myocarditis Following Coronavirus Disease 2019 mRNA Vaccine: A Case Series and Incidence Rate Determination.

BACKGROUND: Myocarditis following coronavirus disease 2019 (COVID-19) mRNA vaccines (Pfizer-BioNTech and Moderna) has been increasingly reported. Incidence rates in the general population are lacking, with pericarditis rather than myocarditis diagnostic codes being used to estimate background rates. This comparison is critical for balancing the risk of vaccination with the risk of no vaccination. METHODS: A retrospective case series was performed using the Mayo Clinic COVID-19 Vaccine Registry. We measured the incidence rate ratio (IRR) for myocarditis temporally related to COVID-19 mRNA vaccination compared with myocarditis in a comparable population from 2016 through 2020. Clinical characteristics and outcomes of the affected patients were collected. A total of 21 individuals were identified, but ultimately 7 patients met the inclusion criteria for vaccine-associated myocarditis. RESULTS: The overall IRR of COVID-19-related myocarditis was 4.18 (95% confidence interval [CI], 1.63-8.98), which was entirely attributable to an increased IRR among adult males (IRR, 6.69; 95% CI, 2.35-15.52) compared with females (IRR 1.41; 95% CI, .03-8.45). All cases occurred within 2 weeks of a dose of the COVID-19 mRNA vaccine, with the majority occurring within 3 days (range, 1-13) following the second dose (6 of 7 patients, 86%). Overall, cases were mild, and all patients survived. CONCLUSIONS: Myocarditis is a rare adverse event associated with COVID-19 mRNA vaccines. It occurs in adult males with significantly higher incidence than in the background population. Recurrence of myocarditis after a subsequent mRNA vaccine dose is not known at this time